336.68 USD
▼-3.35-0.99%
盘后 338.73 0.00%
2026-09-15
市值
$9.97B
市盈率
42.27
EPS
7.97
股息率
—
52 周区间
145.46 – 382.54
成交量
225.77K
Beta
0.54
目标价
385.00
52W 低 145.4652W 高 382.54
价格走势
公司简介
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey...